• Contact us: 01476 247 007
    MHRA post-transition period informationMHRA post-transition period informationMHRA post-transition period informationMHRA post-transition period information
    • How can we help
      • Pharmacovigilance
        • National contact person for pharmacovigilance – post Brexit
        • Pharmacovigilance Standard Operating Procedure Audits
        • Post Marketing Pharmacovigilance Support
        • Clinical Trial Pharmacovigilance Support
        • EU QPPV Provision
        • Quality & Compliance
        • Risk Assessment and Management
        • Signal Detection and Management
      • Medical Writing
      • Patient Information
      • Regulatory
      • Market Authorisation Holding
    • Brexit
    • Our Partners
      • Marti Farm
      • Affiliates
      • Medilink
      • External Team
    • News
    • Get in touch
    Business as usual at Pure Drug Safety despite the continuing coronavirus pandemic
    Business as usual at Pure Drug Safety
    15th May 2020
    What's it like working as an intern at Pure Drug Safety?
    What’s it like to work at Pure Drug Safety – Lottie’s view
    16th September 2020

    MHRA post-transition period information

    3rd September 2020
    MHRA post-transition period information from Pure Drug Safety

    MHRA post-transition period information from Pure Drug SafetyOn Monday 1 September 2020, the MHRA released an update to the guidance on pharmacovigilance post-transitional period and I am sure we all heard the emails pinging into our inboxes all afternoon.

    The document clearly outlines the submission requirements for pharmacovigilance data as from the 1 January 2021.

    As from the 1 January 2021, medicines authorised in Great Britain, all Marketing Authorisation Holders (MAH), will be required to submit pharmacovigilance data to the MHRA, in line with the GB requirements, these include the following:

    • (ICSRs) – UK and non-UK Individual Case Safety Reports
    • (PSURs) – Periodic Safety Update Reports
    • (RMPs) – Risk Management Plans
    • (PASS) Post-Authorisation Safety Studies-protocols and final study reports

    We have all been bombarded with a huge amount of information, so to make things easier for you all our experienced PV Team here at PDS are working through all the updated guidance and breaking it down into bite size pieces.

    Over the coming weeks, we will be adding this information to our website and we will also be updating the key areas that we work within with the new guidance, so please keep an eye on our website for clear and concise updates.

    Click here to visit the MHRA guidance.

    Share

    Related posts

    MHRA post-transition period information from Pure Drug Safety
    23rd October 2020

    MHRA and EMA latest guidance on Brexit


    Read more
    What happens after Brexit for Pharmacovigilance and Regulatory?
    12th February 2020

    What happens after Brexit for Pharmacovigilance and Regulatory?


    Read more
    Pharmacovigilance (QPPV) provision post-Brexit
    7th February 2020

    Pharmacovigilance (QPPV) provision post-Brexit


    Read more

    PLEASE NOTE OUR NEW PHONE NUMBER AS OF 1st JUNE 2021
    Call our team +44(0) 1476 247 007
    email info@puredrugsafety.com



    Sign up for our newsletter

    Pure Drug Safety Ltd

    Pure Drug Safety Ltd · 1 year ago
    @PureDrugSafety



    Many clients have already put their NCPP in place with us here at PDS and are ready for January 2022.

    Read more 👉 https://t.co/6mnM9Dzoma

    #NationalContactPerson #KnowledgeablePerson #ExperiencedQppv https://t.co/rS2W4PZbDv

    View on Twitter


    0

    0

    © 2019 - 2023 Pure Drug Safety.
    As of 1st June 2021 NEW OFFICE & REGISTERED ADDRESS: BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Pure Drug Safety Limited is a company registered in England and Wales. Registered Company Number 7702236. VAT Registered Number 117 966 288
    For our GDPR and Privacy Policy click here
    Designed by Gather Creative | Content managed by Tailored Marketing Solutions | Built + Hosted by GIGER MEDIA